Alcohol Use Disorder in Women: A Comprehensive Clinical and Scientific Overview

Overview

Alcohol use disorder (AUD) in women is no longer a peripheral concern in addiction medicine — it is a central and accelerating public health crisis. Over the past two decades, the historical assumption that AUD is predominantly a male condition has been steadily dismantled by epidemiological data showing that women's rates of heavy drinking, AUD diagnosis, and alcohol-related death are rising faster than men's ^[1]. The gender gap is narrowing. And because women face elevated medical risk at lower levels of alcohol exposure than men — due to real, measurable biological differences — this convergence carries consequences that are disproportionate and urgent.

This article synthesizes evidence from a multi-expert panel discussion drawing on verified research documents. It is designed to serve clinicians, researchers, people in recovery, and anyone seeking a rigorous, person-centered understanding of how AUD affects women differently — biologically, psychologically, socially, and medically. Where the evidence is strong, it is presented as such. Where the corpus has gaps, those gaps are named honestly.

The Narrowing Gender Gap

For most of the twentieth century, men drank more than women, developed AUD at higher rates, and died from alcohol-related causes more often. That pattern is changing — and changing fast.

Recent narrative reviews confirm "an alarming increase in alcohol use and AUD prevalence among women" over the past two decades in the United States, directly narrowing the historical male-female gap ^[1]. Global Burden of Disease 2019 data quantify this shift: among young women, the age-standardized prevalence rate of AUD reached 895.96 per 100,000 (95% uncertainty interval: 722.6–1,103.58), with the highest burdens concentrated in Central Europe and high-income Asia-Pacific regions ^[2].

The scale of the problem is visible in real-world digital health data. Among 41,052 women using the Daybreak digital peer support app between 2019 and 2024, 97.7% scored above the high-risk drinking threshold on the AUDIT-C, and 96.6% met criteria for potential alcohol dependence. The highest-risk scores were concentrated in women aged 35–54. Critically, 57.8% reported high or very high psychological distress — a figure that underscores how inseparable alcohol risk and mental health burden are in this population ^[3].

Despite rising prevalence, women remain significantly underdiagnosed. In a large U.S. cohort, female sex was independently associated with lower odds of receiving an AUD diagnosis even when women screened positive for unhealthy alcohol use ^[4]. This diagnostic gap has direct downstream consequences: an AUD diagnosis is associated with dramatically increased odds of receiving medication (adjusted odds ratio = 10.68; 95% CI: 9.68–11.79) and psychotherapy (aOR = 1.57) ^[4]. Put plainly: the diagnostic gap is the treatment gap.

Sex-Specific Metabolism

Women are not simply smaller men when it comes to alcohol. There are fundamental biological differences in how alcohol is absorbed, distributed, and metabolized — and these differences explain why women experience greater harm at lower doses.

Two mechanisms are central. First, women have lower total body water than men (approximately 50% versus 60% of body weight). Because alcohol distributes through body water, the same amount of alcohol consumed produces a higher blood alcohol concentration (BAC) in a woman than in a man of equivalent weight [corpus-gap]. Second, women have less gastric alcohol dehydrogenase (ADH) activity — the enzyme responsible for first-pass metabolism of alcohol in the stomach. Less first-pass metabolism means more alcohol reaches the systemic circulation unchanged. The combined effect is straightforward: the same number of drinks produces a meaningfully higher BAC in women than in men.

These pharmacokinetic differences are not subtle. They are the biological foundation for sex-specific drinking guidelines — national recommendations that define "low-risk" drinking at lower thresholds for women than for men ^[5]. They also explain why women develop alcohol-related organ damage faster and at lower lifetime exposures than men — a pattern documented across the liver, heart, and brain.

Telescoping

"Telescoping" is the clinical term for a phenomenon first documented in opioid use disorder and subsequently extended to alcohol: women progress from first drink to problematic drinking faster than men, and from problematic drinking to severe medical complications faster than men. The trajectory that might take a man decades to traverse can take a woman years.

The evidence for telescoping in AUD is well-established. Women present to treatment with more severe AUD and more complex psychological, social, and service needs than men, despite often having shorter drinking histories ^[6]. This is not a marginal difference in severity — it reflects a compressed timeline of harm accumulation.

The clinical implication is significant: intervention windows for women are earlier and narrower. Waiting for a woman to "hit bottom" in the way that framing has historically been applied to men may mean waiting until organ damage is already advanced. Earlier, proactive screening — using sex-specific thresholds — is essential.

Medical Consequences: Liver Disease

Alcohol-associated liver disease (ALD) is among the most serious and well-documented sex-specific consequences of AUD. Women develop ALD at lower lifetime alcohol exposures than men, progress to cirrhosis faster, and experience worse outcomes once liver disease is established ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

Global Burden of Disease 2019 data quantify the hepatological burden in young women specifically: age-standardized prevalence of alcohol-associated cirrhosis reached 65.33 per 100,000 (95% UI: 48.37–86.49), with cirrhosis mortality at 0.75 per 100,000 (95% UI: 0.55–0.97) ^[2]. Young women display "higher susceptibility" to these complications compared to male counterparts — a finding that directly challenges any assumption that liver disease is primarily a concern for older or male patients.

The corpus documents the epidemiological intersection of AUD and ALD in women clearly ^{[1] [2]}. However, an important gap must be acknowledged: the corpus does not contain mechanistic hepatology studies detailing the precise biological pathways — such as estrogen effects on hepatic inflammation or sex differences in oxidative stress responses — that explain women's heightened vulnerability. The phenomenon is established; the mechanisms require additional documentation.

Critically, no document in the corpus connects treatment engagement or recovery to downstream liver disease outcomes in women. We can infer that reducing alcohol consumption would benefit the liver, but the evidence base does not yet close that loop with data. This is a significant gap in a field where the stakes are high.

Medical Consequences: Breast Cancer

The relationship between alcohol consumption and breast cancer risk is one of the most robustly documented dose-response relationships in cancer epidemiology — and it begins at low levels of exposure.

Research establishes approximately a 7–10% increase in breast cancer risk per standard drink per day, with no clearly safe lower threshold ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This is not a risk confined to heavy drinkers. A woman consuming one drink per day faces meaningfully elevated breast cancer risk compared to a non-drinker. The relationship is linear and begins at exposures well below what many people consider "moderate" drinking.

This finding carries direct implications for clinical counseling. Women who drink — even at levels that fall within conventional "low-risk" guidelines — should be informed of this relationship as part of shared decision-making about alcohol use. The breast cancer risk is a counseling point that belongs in every conversation about alcohol and women's health, not only in conversations about AUD.

Medical Consequences: Cardiovascular

The cardiovascular consequences of alcohol use in women follow the same pattern seen in liver disease: greater harm at lower exposures than men. Women develop alcohol-related cardiomyopathy at lower levels of consumption, and face elevated risks of hypertension and stroke.

A meta-analysis of 23 prospective studies involving 489,696 individuals found that women with moderate alcohol intake had a significantly increased relative risk ratio for total mortality compared to men at equivalent intake levels (RRR 1.10; 95% CI: 1.00–1.21; P = 0.047) ^[7]. This finding is important because it directly challenges the long-held belief that moderate drinking confers cardiovascular benefit — a belief that, for women, appears to be either absent or substantially offset by other harms.

The panel notes that recent analyses suggest the apparent "moderate drinking benefit" documented in older studies was likely confounded by methodological problems, including the inclusion of former drinkers (who quit due to illness) in the "abstainer" comparison group. The corpus supports skepticism about cardiovascular benefit claims, particularly for women ^[7].

All-Cause Mortality

The mortality data reinforce the pattern established across organ systems. Women's all-cause mortality rises at lower alcohol exposures than men's. The meta-analytic evidence from Zheng et al. (2015) — 23 prospective studies, nearly half a million individuals — documents that even moderate intake is associated with elevated total mortality risk in women relative to men ^[7].

This is the biological signature of female vulnerability to alcohol: not just greater harm in specific organ systems, but greater harm in aggregate, at lower doses, across the lifespan.

Trauma Comorbidity

Trauma is not a background variable in women's AUD — it is frequently a central driver. Women with AUD show significantly higher rates of PTSD, depression, anxiety, and eating disorders compared to men with AUD ^[8] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Women veterans with AUD report significantly higher anxiety, depression, early life stress, and PTSD than their male counterparts at baseline ^[9].

Psychiatric comorbidities — particularly depression and PTSD — substantially elevate suicide risk in alcohol-dependent women ^[10]. This is a clinical emergency hiding in plain sight: women with AUD are not simply drinking too much; many are managing the aftermath of trauma with the only tool that felt available.

The strongest experimental evidence on integrated trauma-AUD treatment comes from Persson et al. (2025), an RCT of 90 women with current PTSD and moderate-to-severe AUD. Participants were randomized to either integrated trauma-focused treatment (the COPE protocol — Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure) or relapse prevention alone. Results showed:

• PTSD symptom severity (CAPS-5) decreased significantly more in the integrated arm (mean scores: 37.40 → 13.18) than in relapse prevention (39.09 → 23.68), with a significant treatment-by-time interaction (F₄,₁₅₅ = 3.0; p = .02)
• Alcohol use decreased significantly in both arms, with no detectable between-group difference ^[11]

This finding is landmark for two reasons. First, it demonstrates that trauma-focused treatment is safe and effective even with ongoing alcohol use — directly countering the historical clinical reluctance to offer trauma-focused therapy to patients with active substance use. Second, it shows that treating PTSD more effectively does not automatically produce superior alcohol outcomes over a 9-month horizon. Both domains require direct intervention; neither can substitute for the other.

A complementary pilot study of integrated group treatment for co-occurring depression and AUD in women showed high feasibility, credibility, and patient satisfaction, with reductions in both depression severity and alcohol consumption ^[12]. Importantly, the pilot also documented negative effects — specifically increased adverse emotional experiences — flagging that integrated treatment carries clinical risks requiring careful management. Randomized trials are still needed to establish efficacy.

The corpus does not contain documents specifically addressing sexual trauma as a distinct subtype within AUD-PTSD comorbidity. This is a significant gap, given that sexual trauma is among the most common PTSD precipitants in women with AUD. Gender-sensitive addiction care that specifically addresses psychosocial stressors and trauma is advocated in the literature ^[13], but the corpus cannot support detailed claims about sexual trauma's specific role in AUD etiology or treatment response.

Depression and Anxiety Comorbidity

Women with AUD are significantly more likely than men to present with comorbid mood and anxiety disorders . Men with AUD more commonly present with externalizing disorders. This difference in comorbidity profile has direct implications for treatment design: programs built around confrontational or externalizing-focused models may be poorly matched to women's presentations.

A pilot study of integrated group treatment for depression and AUD in women demonstrated that addressing both conditions simultaneously is feasible and acceptable to participants, with concurrent decreases in depression severity and alcohol consumption ^[12]. The signal is encouraging, but the evidence base for depression-AUD integrated treatment in women remains at the pilot stage. Integrated treatment — not sequential, not siloed — is the direction the evidence points.

Treatment Outcomes

When women do access treatment, they do as well as or better than men on measured outcomes ^[6]. The problem is not that treatment fails women — it is that women face compounding barriers that prevent them from reaching treatment in the first place.

McCrady et al. (2020) synthesize the evidence on what works: women-only programs that include female-specific content, provision of childcare, prenatal care, treatment for co-occurring psychological problems, and supplemental social services produce better outcomes than generic, mixed-gender, or single-domain approaches ^[6]. These elements are not alternatives — they function as a package. Removing structural barriers without addressing psychiatric comorbidity leaves the underlying drivers of drinking unaddressed. Treating trauma without solving childcare means a woman cannot get to the appointment.

On long-term outcomes, the corpus is honest about its limits. Tucker et al. (2020) note that approximately 70% of persons with AUD improve without formal intervention, and that sex differences are more apparent in help-seeking than in recovery patterns — once the selection effect of lower help-seeking in women is accounted for, recovery trajectories do not differ dramatically by sex ^[14] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This is an important corrective to assumptions that women necessarily have worse long-term outcomes. However, the current corpus does not contain a longitudinal study tracking women from treatment completion through multi-year recovery maintenance. What predicts durable recovery versus relapse cycling in women, over years and decades, remains largely unanswered.

Recovery capital — the internal and external resources that support sustained recovery — shows consistent protective effects. In a national sample of adults with resolved AUD, recovery capital was associated with lower odds of mild relapse for women (aOR 0.90; 95% CI: 0.84–0.97) ^[15]. Building recovery capital — through social connection, employment, housing stability, and peer support — is not a soft add-on to treatment; it is a documented protective mechanism.

Women-Only and Gender-Specific Programs

The evidence supports gender-specific treatment options as a meaningful component of the care landscape. McCrady et al. (2020) state explicitly that outcomes for women are best when treatment is provided in women-only programs that include female-specific content ^[6]. Programs such as Women for Sobriety (WFS), Seeking Safety women's groups, women's-only residential programs, and survivor-specific tracks represent this model in practice.

The rationale is not merely comfort — it is clinical. Women-only settings reduce the social dynamics that can inhibit disclosure of trauma, sexual violence, and stigmatized experiences. They allow treatment content to be calibrated to women's specific comorbidity profiles, relational contexts, and recovery pathways. The COPE trial, conducted exclusively in women, provides the strongest evidence that this approach can produce meaningful psychiatric outcomes ^[11].

Pharmacotherapy

Pharmacological treatment for AUD — including naltrexone, acamprosate, topiramate, and disulfiram — is an evidence-based component of comprehensive care. However, a critical gap must be named directly: only 5.9% of pharmacological AUD trial articles conducted subgroup analyses by sex, and women have been systematically underrepresented in trials of all major AUD medications ^[6]. The evidence base for sex-specific pharmacological efficacy is thin.

What the corpus can support: naltrexone and acamprosate show comparable efficacy in women and men based on available data, with some pharmacogenetic data on OPRM1 variants relevant to naltrexone response. Topiramate shows comparable efficacy but carries a pregnancy contraindication due to risk of cleft palate in the fetus. Disulfiram similarly carries a pregnancy contraindication. Hormonal interactions with AUD medications — how the menstrual cycle, hormonal contraception, or menopause might affect medication pharmacokinetics or efficacy — represent a significant evidence gap that the corpus cannot address.

The underrepresentation of women in pharmacotherapy trials is not a minor methodological footnote. It means that the medications most commonly prescribed for AUD were largely developed and tested in male samples, with findings extrapolated to women. Sex-stratified pharmacotherapy outcomes research is an urgent priority.

Pregnancy and Postpartum

Pregnancy and the postpartum period represent a high-stakes window for women with AUD. The postpartum period in particular is a high-relapse window — a time when the stressors of new parenthood, sleep deprivation, social isolation, and the loss of pregnancy-related motivation to abstain can converge to increase drinking risk.

Trauma-informed prenatal care is essential for women with AUD, given the high rates of trauma comorbidity documented throughout this corpus [corpus-gap]. Fear of child protective services involvement is a documented barrier to treatment-seeking for pregnant and parenting women [corpus-gap] — a barrier that, if not actively addressed, can prevent women from accessing care precisely when the stakes are highest.

The corpus does not contain detailed documentation of fetal alcohol spectrum disorder (FASD) prevention or perinatal AUD treatment outcomes. This is a significant clinical gap.

No Safe Amount of Alcohol During Pregnancy

The clinical consensus on alcohol and pregnancy is unambiguous: no amount of alcohol is known to be safe at any point during pregnancy. ASAM, the American College of Obstetricians and Gynecologists (ACOG), the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) all align on this position and recommend complete abstinence from alcohol throughout pregnancy — including in the period before a pregnancy is confirmed.

This is not a precautionary overcorrection. There is no identified threshold below which alcohol exposure carries zero risk of harm to fetal development. Fetal alcohol spectrum disorders (FASDs) — the range of physical, behavioral, and intellectual disabilities that can result from prenatal alcohol exposure — are entirely preventable, and entirely caused by alcohol use during pregnancy. Because the risk begins before many women know they are pregnant, the recommendation for abstinence extends to anyone who is pregnant or trying to become pregnant.

For women with alcohol use disorder (AUD) — sometimes called alcoholism or alcohol addiction — pregnancy does not eliminate the need for treatment. It makes it more urgent. ASAM's position is that AUD in pregnancy requires specialized, integrated care that coordinates addiction medicine with obstetrics and, where available, maternal-fetal medicine. This is not a setting where a single provider working alone is the appropriate model.

Pharmacotherapy decisions during pregnancy are made on a case-by-case basis, weighing maternal and fetal risks carefully. Naltrexone, acamprosate, and disulfiram — the medications most commonly used in AUD treatment — do not have established safety profiles in pregnancy, and their use requires individualized clinical judgment in consultation with specialists. Notably, topiramate and disulfiram carry specific contraindications in pregnancy. Untreated AUD in pregnancy, however, also carries serious risks — including alcohol withdrawal, which can be medically dangerous for both the pregnant person and the fetus. The decision to use or withhold pharmacotherapy must weigh those risks explicitly, not default to inaction.

A documented barrier to care in this population is fear of child protective services involvement. Pregnant women with AUD who avoid disclosing their drinking — or avoid prenatal care entirely — because they fear legal consequences are not being served by a system that treats disclosure as a liability. Trauma-informed, non-punitive prenatal care that actively reduces this barrier is not only ethically appropriate; it is clinically necessary to reach the women who need care most.

The corpus does not contain clinical trial data on perinatal AUD treatment outcomes or FASD prevention program efficacy. That evidence gap does not weaken the consensus position — it reflects how underinvested this area of research has been. The authoritative guidance from ASAM, ACOG, CDC, AAP, and NIAAA is clear and consistent: complete abstinence, integrated care, and individualized pharmacotherapy decisions made in partnership with maternal-fetal medicine specialists.

Hormonal Cycle and Menopause

Drinking patterns vary across the menstrual cycle for some women, with premenstrual escalation documented in a subset. The biological mechanisms — including fluctuations in estrogen and progesterone that affect stress reactivity and reward processing — are plausible and consistent with the broader literature on hormonal influences on addiction, but the corpus does not provide detailed mechanistic documentation of this relationship.

Menopause represents a distinct risk window. Sleep disruption, mood changes, and the use of alcohol to manage hot flashes and anxiety can drive increased drinking in midlife and older women. The Daybreak data showing peak AUDIT-C scores in women aged 35–54 ^[3] are consistent with this pattern, though the corpus cannot establish causation from this cross-sectional finding.

Older Adult Women

Late-onset AUD in women is a recognized clinical pattern, often following bereavement, retirement, or other major life transitions that disrupt social structure and purpose. Tryggedsson et al. (2025) examined outcomes in 693 older adults (including women) receiving motivational enhancement and community reinforcement approaches, finding substantial and gender-comparable improvements in drinks per day and abstinence sustained at one-year follow-up — though women showed slightly smaller reductions after adjustment ^[16]. This suggests that older women respond to treatment, but may require tailored approaches that account for the specific precipitants and social contexts of late-onset AUD.

LGBTQ Women

Lesbian and bisexual women experience higher rates of AUD than heterosexual women, a pattern consistently attributed to minority stress — the chronic psychological burden of stigma, discrimination, and concealment. Treatment programs should be explicitly affirming of LGBTQ identities, and clinicians should be aware that standard screening and treatment tools may not capture the specific stressors driving alcohol use in this population. The corpus documents elevated AUD rates among sexual minority women ^{[17] [18]} but does not contain detailed intervention studies specifically targeting this group. This is a gap.

Women Veterans

Women veterans represent a population at the intersection of multiple risk factors: high rates of military sexual trauma (MST), PTSD-AUD comorbidity, and the specific stressors of military service and transition to civilian life. Craft et al. (2025) document that women veterans with AUD report significantly higher anxiety, depression, early life stress, and PTSD than male veterans with AUD at baseline ^[9]. Notably, gender was not associated with relapse or severity of use at 6 months post-study — suggesting that when women veterans access treatment, they achieve comparable outcomes to men ^[9].

Women's-track VA programs and MST-specific treatment pathways represent the appropriate clinical response to this population's needs. The corpus supports the importance of trauma-informed, gender-specific care for women veterans, consistent with the broader evidence on integrated treatment.

Access Barriers

The barriers that prevent women from accessing AUD treatment are well-documented and compounding. They include:

• Stigma — particularly intense for mothers, who face social judgment that men with AUD typically do not [corpus-gap]
• Fear of child protective services involvement — a documented deterrent to treatment-seeking among parenting women [corpus-gap]
• Childcare responsibilities — making in-person treatment logistically impossible without support ^[19]
• Geographic isolation and transportation — particularly in rural settings
• Financial barriers — including inability to take time off work
• Self-stigma — particularly pronounced among marginalized women, including those who are incarcerated ^[20]

Programs that solve these barriers are accessible; programs that don't, aren't. Ross et al. (2024) recommend universal screening, provider education, childcare provision, and virtual prescribing as structural enablers ^[19]. Digital recovery support services show promise: women with minor children in the household had higher odds of using digital recovery support (aOR 3.58), as did unemployed women (aOR 9.85) and those with greater AUD symptom counts (aOR 1.30) ^[21]. Digital platforms may reach women who cannot or will not access traditional in-person care — but the corpus reports only engagement data, not recovery outcomes, from these platforms ^[3].

Evidence Gaps

Honest science names what it does not know. The expert panel identified the following significant gaps in the current evidence base:

1. Historical underrepresentation in AUD research. Much of the foundational AUD research was conducted on male samples, with findings extrapolated to women. Sex-specific data are growing but remain insufficient across most domains ^[6].

2. Sex-stratified pharmacotherapy outcomes. Only 5.9% of pharmacological AUD trial articles conducted subgroup analyses by sex ^[6]. Strong evidence-based claims about sex-specific efficacy for naltrexone, acamprosate, topiramate, or disulfiram cannot yet be made from the current corpus.

3. Hormonal interactions with medication. How the menstrual cycle, hormonal contraception, or menopause affects AUD medication pharmacokinetics or efficacy is essentially undocumented in this corpus.

4. Long-term recovery trajectories in women. The current corpus does not include a longitudinal study tracking women from treatment completion through multi-year recovery maintenance. What predicts durable recovery versus relapse cycling — and whether integrated psychiatric-addiction care reduces long-term relapse rates — remains unanswered.

5. Treatment engagement linked to liver disease outcomes. No document in the corpus connects AUD treatment engagement or recovery to downstream liver disease outcomes in women. The epidemiological burden is documented; the treatment-to-organ-outcome pathway is not.

6. Sexual trauma as a distinct subtype. The corpus does not contain documents specifically addressing sexual trauma as a distinct precipitant within AUD-PTSD comorbidity in women — a significant gap given its clinical prevalence.

7. Perinatal AUD. The corpus is thin on perinatal AUD treatment outcomes, FASD prevention, and postpartum relapse trajectories.

8. LGBTQ-specific interventions. Elevated AUD rates in lesbian and bisexual women are documented, but intervention studies targeting this population are absent from the corpus.

Conclusion

The evidence is clear on the fundamentals: AUD in women is rising, the gender gap is narrowing, and women face elevated medical risk at lower exposures than men — in the liver, the heart, and across all-cause mortality. Telescoping means the window for intervention is earlier and narrower. Trauma, particularly PTSD, is a central driver of women's AUD that treatment systems have historically failed to address. Integrated, women-specific, trauma-informed care — with structural supports including childcare and stigma reduction — represents the evidence-supported standard.

What the evidence cannot yet tell us is whether we are actually changing long-term trajectories. The corpus documents who is at risk and what to offer acutely. The longitudinal story — whether integrated care sustains recovery, prevents liver disease, and changes the arc of women's lives over years and decades — remains to be written. That is not a reason for inaction. It is a reason for urgency: in research, in clinical design, and in the political will to build treatment systems that actually meet women where they are.

This article synthesizes a multi-expert panel discussion grounded in verified research documents. All citations reflect papers cited by panel experts. Gaps in the evidence base are noted explicitly throughout.

Verified References

• ^[10] Abid-Chapon, Nelly, Rasho, Abdul Rahman, Delouvée, Sylvain (2025). "Preventing Suicide Among Alcohol-Dependent Women: A Scoping Review of Clinical and Socio-Cultural Factors.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2478605 [abstract-verified: partial]
• ^[6] Ammit, Melise, River, Jo, Montebello, Mark et al. (2025). "Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic review.". Womens Health (Lond). DOI: 10.1177/17455057251363713 [abstract-verified: partial]
• ^[1] Carlini, Lauren E, Fernandez, Anne C, Mellinger, Jessica L (2026). "Sex and gender in alcohol use disorder and alcohol-associated liver disease in the United States: A narrative review.". Hepatology. DOI: 10.1097/hep.0000000000000905 [abstract-verified: partial]
• ^[9] Craft, William H, Padula, Claudia B (2025). "Rethinking gender differences: An investigation of comorbid psychopathology and alcohol use disorder in veterans.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.15505 [abstract-verified: partial]
• ^[2] Danpanichkul, Pojsakorn, Ng, Cheng Han, Muthiah, Mark et al. (2024). "From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women.". Am J Gastroenterol. DOI: 10.14309/ajg.0000000000002642 [abstract-verified: partial]
• ^[17] Evans-Polce, Rebecca J, Kcomt, Luisa, Veliz, Philip T et al. (2020). "Alcohol, Tobacco, and Comorbid Psychiatric Disorders and Associations With Sexual Identity and Stress-Related Correlates.". Am J Psychiatry. DOI: 10.1176/appi.ajp.2020.20010005 [abstract-verified: partial]
• ^[13] Friedel, Eva, Müller-Wirth, Nina, Buspavanich, Pichit et al. (2026). "[Impact of gender roles on alcohol dependence].". Nervenarzt. DOI: 10.1007/s00115-025-01904-9 [abstract-verified: partial]
• ^[15] Gilbert, Paul A, Soweid, Loulwa, Kersten, Sarah K et al. (2021). "Maintaining recovery from alcohol use disorder during the COVID-19 pandemic: The importance of recovery capital.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2021.109142 [abstract-verified: yes]
• ^[21] Gilbert, Paul A, Saathoff, Elizabeth, Russell, Alex M et al. (2022). "Gender differences in lifetime and current use of online support for recovery from alcohol use disorder.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14827 [abstract-verified: partial]
• ^[6] Barbara S McCrady, Elizabeth E Epstein, Kathryn F Fokas (2020). "Treatment Interventions for Women With Alcohol Use Disorder.". Alcohol research : current reviews. DOI: 10.1080/10550887.2013.795465 [abstract-verified: partial]
• ^[20] Moore, Kelly E, Stein, Michael D, Kurth, Megan E et al. (2020). "Risk Factors for Self-stigma among Incarcerated Women with Alcohol Use Disorder.". Stigma Health. DOI: 10.1037/sah0000182 [abstract-verified: yes]
• ^[18] Mulia, Nina, Bensley, Kara M (2020). "Alcohol-Related Disparities Among Women: Evidence and Potential Explanations.". Alcohol Res. DOI: 10.35946/arcr.v40.2.09 [abstract-verified: partial]
• ^[11] Persson, Anna, Axén, Åsa, Capusan, Andrea Johansson et al. (2025). "Concurrent Treatment of Posttraumatic Stress Disorder and Alcohol Use Disorder in Women: A Randomized Clinical Trial.". JAMA Netw Open. DOI: 10.1001/jamanetworkopen.2025.21087 [abstract-verified: yes]
• ^[12] Persson, Anna, Finn, Daniel Wallhed, Broberg, Alice et al. (2025). "Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol use disorder care - a pilot study.". Front Psychiatry. DOI: 10.3389/fpsyt.2025.1473988 [abstract-verified: partial]
• ^[3] Robinson, Laura D, Ingram, Isabella, Degan, Tayla J et al. (2026). "Alcohol Use, Demographics and Mental Health of Women Using a Digital Peer Support Program.". Health Promot J Austr. DOI: 10.1002/hpja.70161 [abstract-verified: yes]
• ^[19] Ross, Hayley, Kurbatfinski, Stefan, Szelest, Izabela (2024). "Investigating the unique service and treatment needs of women with alcohol use disorder: Literature review and key informant perspectives in British Columbia.". Healthc Manage Forum. DOI: 10.1177/08404704241229973 [abstract-verified: partial]
• ^[5] Schettini, Greta, Johansson, Magnus, Andersson, Sam et al. (2024). "Is internet-based cognitive behavioral therapy for alcohol use disorder equally effective for men and women? Implications of a secondary analysis of a clinical trial.". Front Psychiatry. DOI: 10.3389/fpsyt.2024.1486278 [abstract-verified: partial]
• ^[6] Schick, Melissa R, Spillane, Nichea S, Hostetler, Katherine L (2020). "A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14440 [abstract-verified: partial]
• ^[16] Tryggedsson, Jeppe Sig Juelsgaard, Andersen, Kjeld, Behrendt, Silke et al. (2025). "Exploring the role of gender on treatment outcomes in older adults with alcohol use disorder.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.70164 [abstract-verified: partial]
• ^[4] Yue, Yihua, Rothberg, Michael B, Back, Sudie E et al. (2026). "Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.". J Gen Intern Med. DOI: 10.1007/s11606-025-10089-5 [abstract-verified: yes]
• ^[7] Zheng, Yan-Ling, Lian, Feng, Shi, Qian et al. (2015). "Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men: a systematic review and meta-analysis of prospective observational studies.". BMC Public Health. DOI: 10.1186/s12889-015-2081-y [abstract-verified: partial]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[22] → ^[1] (verifier: partial; score 0.80). Title: The indirect effect of negative emotionality via alcohol craving on abstinence self-efficacy among women in alcohol trea
• ^[23] → ^[24] (verifier: partial; score 0.80). Title: Alcohol Consumption and Risk of Hospitalizations and Mortality in the Atherosclerosis Risk in Communities Study.
• ^[23] → ^[12] (verifier: partial; score 0.78). Title: Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol
• ^[25] → ^[1] (verifier: partial; score 0.78). Title: The indirect effect of negative emotionality via alcohol craving on abstinence self-efficacy among women in alcohol trea
• ^[25] → ^[26] (verifier: partial; score 0.86). Title: ACG Clinical Guideline: Alcohol-Associated Liver Disease.
• ^[27] → ^[2] (verifier: yes; score 0.63). Title: Macro-level determinants of gender differences in the prevalence of major depression and alcohol use disorder in the Uni
• ^[28] → ^[3] (verifier: partial; score 0.75). Title: Multifaceted case management during pregnancy is associated with better child outcomes and less fetal alcohol syndrome.
• ^[28] → ^[21] (verifier: partial; score 0.69). Title: Characteristics of clients entering women-only substance use treatment services in New South Wales.
• ^[29] → ^[5] (verifier: yes; score 0.76). Title: Alcohol use disorder in community management of chronic liver diseases.
• ^[30] → ^[6] (verifier: partial; score 0.77). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[30] → ^[12] (verifier: yes; score 0.79). Title: Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol
• ^[31] → ^[7] (verifier: partial; score 0.87). Title: Alcoholism: A Multi-Systemic Cellular Insult to Organs.
• ^[31] → ^[7] (verifier: partial; score 0.76). Title: Alcoholism: A Multi-Systemic Cellular Insult to Organs.
• ^[32] → ^[11] (verifier: yes; score 0.63). Title: Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
• ^[33] → ^[13] (verifier: partial; score 0.74). Title: Integrated Cognitive Processing Therapy and Relapse Prevention for Co-Occurring PTSD and Alcohol Use Disorder: A Case Se
• ^[34] → ^[6] (verifier: partial; score 0.66). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[34] → ^[35] (verifier: partial; score 0.66). Title: Gender differences in lifetime and current use of online support for recovery from alcohol use disorder.
• ^[36] → ^[19] (verifier: partial; score 0.77). Title: _Cross-sectional study of the rates of military sexual trauma (MST) and associations with adverse mental health outcomes _
• ^[37] → ^[16] (verifier: partial; score 0.72). Title: _Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder - _
• ^[6] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[35] → ^[21] (verifier: partial; score 0.67). Title: Characteristics of clients entering women-only substance use treatment services in New South Wales.